Oxford Industries Limited has appointed Managing Director Saroj Kumar Choudhury as its new CFO following a successful promoter takeover. The board also proposed a 99% capital reduction to write off losses, an out-of-state corporate relocation, and a major strategic pivot into the healthcare and pharmaceutical sectors.
MUMBAI — Oxford Industries Limited announced on Friday, July 17, 2026, that its Board of Directors has formally appointed its current Managing Director, Mr. Saroj Kumar Choudhury, as the company's new Chief Financial Officer (CFO). The strategic appointment, effective immediately, coincided with a sweeping overhaul of the micro-cap company’s management structure, operational goals, and capitalization strategy.
Meeting at its corporate headquarters in Mumbai, Maharashtra, the board finalized a takeover open offer, proposed a dramatic 99% capital reduction to offset accumulated business losses, and drafted plans to shift its entire corporate base out of state. Most notably, the company announced its intention to expand its commercial focus away from traditional textiles to enter the pharmaceutical, diagnostic, and healthcare sectors.
Strategic Shift and Management Takeover
According to official regulatory submissions delivered to market watchdogs, the board meeting commenced at 4:00 P.M. and wrapped up at 5:40 P.M.. During this session, the company confirmed that the operational open offer triggered by Mr. Saroj Kumar Choudhury under Regulations 3 and 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, has been fully executed. Managed by merchant banking firm M/s. Navigant Corporate Advisors Ltd., the underlying Share Purchase Agreement (SPA) transactions between Mr. Choudhury, former promoter Mr. Mazher N. Laila, and his Persons Acting in Concert (PACs) have concluded.
With the transaction finalized, Mr. Choudhury has transitioned to become the absolute promoter of the enterprise, holding 27,61,576 equity shares, which represent a dominant 46.46% of the company's total paid-up share capital. Conversely, the previous promoter group led by Mr. Mazher N. Laila has ceased all promotional classifications and has been reclassified into public shareholding pools under the provisions of Regulation 31A(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
To streamline executive operations under this new structure, the board appointed Mr. Choudhury to serve in a dual role as the Chief Financial Officer (CFO). Corporate records indicate that Mr. Choudhury brings over 25 years of institutional experience across IT infrastructure management, budget optimization, vendor negotiations, and project management across captive and service industries.
Pivoting Corporate Objects Toward Pharmaceuticals
In tandem with the leadership change, the board proposed an enlargement of the Main Object Clause of its Memorandum of Association (MOA) by inserting sub-clauses 3(a)(3), 3(a)(4), and 3(a)(5). This regulatory modification signifies a major shift into medical markets.
The new operational guidelines authorize the firm to purchase, lease, build, run, and administer hospitals, diagnostic labs, nursing homes, and clinical research facilities. Furthermore, the company will initiate manufacturing, trade, export, and import programs targeting pharmaceuticals, non-prescription drugs, cosmetics, injectables, tablets, and medical-chemical compounds. The expansion plans also include hospital consulting services and the deployment of software systems to manage digital patient records, radiology networks, and clinical insurance processes.
Relocation Plans and Internal Auditing Reorganization
The board also approved two critical structural alterations:
Corporate Relocation: The firm will shift its registered corporate office away from Mumbai, Maharashtra, to the state of Orissa. This physical relocation will be submitted to general voters for final passage at the upcoming Annual General Meeting.
Statutory Auditor Shift: The board recorded the resignation of M/s. PAMS & Associates, Chartered Accountants, effective June 19, 2026. The firm stepped down due to geographical limitations, noting that its main office in Bhubaneswar, Orissa, made it operationally difficult to service the Mumbai-based facilities. As a replacement, the board approved the selection of M/s. Lipika & Associates, Chartered Accountants, to serve a five-year term from financial years 2026–2027 through 2030–2031, pending shareholder ratification.
99% Share Capital Reduction to Offset Accumulated Losses
To address its historical balance sheet imbalances, the board proposed a radical internal corporate restructuring via Section 66 of the Companies Act, 2013. The plan calls for a formal reduction of the company's existing issued and paid-up share capital by a striking 99%.
Corporate leadership stated that this capital reduction is necessary to erase historical accumulated business losses and restore the company's financial balance. The proposal has been submitted to the company's internal Audit Committee for oversight, and a certified registered valuer has been assigned to construct an official valuation report.
Impact on Retail Investors and Stock Markets
For standard retail investors tracking equity developments on the BSE Limited exchange under listing code 514414, these resolutions represent a total transformation of the underlying asset. While a 99% share capital reduction significantly scales down outstanding share allocations to offset losses, the entry of a new promoter, combined with a total pivot into the healthcare sector, completely resets the company's commercial risk-reward profile. Public shareholders will have the opportunity to review, debate, and vote on the capital reduction, the out-of-state move, and the new object clauses at the upcoming Annual General Meeting.
Official Sources Section
According to official corporate updates delivered under Regulation 30 of the SEBI Listing Regulations, all items remain subject to statutory clearances. The transition procedures align with requirements outlined in SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026.
Quote Section
"According to officials at Oxford Industries Limited, the board has approved the change of management alongside the appointment of Mr. Saroj Kumar Choudhury as CFO, while moving forward with proposals for a 99% share capital reduction to neutralize accumulated financial losses."
Why It Matters
The total restructuring at Oxford Industries highlights how smaller listed corporate shells can be repurposed to target higher-growth industrial sectors. By restructuring its balance sheet through a steep capital reduction and installing its main acquirer as CFO, the business is positioning itself to pivot into the pharmaceutical and clinical software markets. The planned relocation to Orissa also helps align its geographic footprint with its new strategic goals.
Key Facts at a Glance
Executive CFO Appointment: Managing Director Mr. Saroj Kumar Choudhury officially steps into the dual role of Chief Financial Officer.
Promoter Takeover Concluded: Mr. Choudhury becomes the controlling promoter, securing a 46.46% stake in the company's paid-up capital.
99% Capital Reduction: The board has proposed cutting share capital by 99% under Section 66 to write off accumulated business losses.
Healthcare Business Pivot: The company is expanding its Main Object Clause to venture into pharmaceuticals, diagnostic laboratories, and hospital operations.
Corporate Relocation: Plans are underway to shift the company's registered headquarters from Maharashtra to Orissa.
FAQ Section
Q1: Why is Oxford Industries initiating a 99% capital reduction?
The capital reduction is being executed under Section 66 of the Companies Act to write off historical accumulated business losses, helping to clear the balance sheet for future operations.
Q2: What industry is Oxford Industries moving into?
The company is pivoting from its historical textile foundation to establish operations in the pharmaceutical, cosmetic, clinical laboratory, diagnostic imaging, and hospital management sectors.
Q3: Who is the incoming statutory auditor for the firm?
Following the resignation of M/s. PAMS & Associates due to geographic constraints, the board has proposed M/s. Lipika & Associates for a five-year tenure.
Q4: When do these major corporate shifts take effect?
The appointment of the new CFO is effective immediately, while the capital reduction, headquarter relocation, and object clause amendments await formal approval at the upcoming Annual General Meeting.
Source: Oxford Industries Limited Corporate Relations Desk, BSE Limited Corporate Announcement Portal.
